Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Participants from an ongoing observational study (P05319) who have a limited (adequate but
less than optimal) response to infliximab will be randomized to either increase the frequency
of infliximab infusions from every 8 weeks to every 6 weeks, or to add weekly methotrexate to
their current treatment plan. While receiving infliximab study treatment(s), patients in this
study will attend regularly scheduled office visits for various clinical tests for safety and
effectiveness evaluations.